相关实验视频

Updated: May 1, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

针对HER3的抗体药物结合治疗固体瘤:最近的进展和未来的潜力

Xuerui Wang^1,2,3, Linlin Zhao^1,2,3, Fangfang Gao⁴

¹Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, 300381, China.

Current medicinal chemistry

|February 25, 2025

概括

抗体-药物结合物 (ADC) 通过将向抗体与强效化疗相结合,可以改善癌症治疗. 针对HER3的ADC对固体瘤有前途,但需要更多的研究来证实它们的有效性和安全性.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
生物技术是生物技术.

背景情况:

标准的癌症治疗方法在有效性和全身毒性方面存在局限性.
抗体-药物结合物 (ADC) 代表了一项进步,将向的单克隆抗体与细胞毒性有效载荷合并.
皮表皮生长因子受体 (EGFR) 家族,包括HER3,是ADC治疗的关键标,原因是瘤中的差异表达.

研究的目的:

审查HER3向ADCs在治疗固体瘤方面的最新进展和未来潜力.
突出显示HER3作为治疗点的重要性,特别是在克服治疗耐药性方面.
要强调需要进一步的临床数据HER3-ADC有效性和安全性在固体恶性瘤.

主要方法:

对抗体-药物结合物 (ADC) 技术近期进展的文献综述.
分析HER3在癌症病原和治疗耐药性中的作用.
检查针对固体瘤的HER3向ADC的潜力和挑战.

主要成果:

由于它与各种癌症的治疗耐药性有关,HER3是ADC的有希望的目标.
固体瘤对HER3-ADC的发展具有重要机会,尽管目前的研究有限.
现有研究表明,ADCs有潜力通过将抗体特异性与细胞毒药物疗效相结合来改善向癌症治疗.

结论:

向HER3的ADC在治疗固体瘤方面具有显著的前景,特别是那些对其他疗法有抗性的瘤.
进一步的临床试验至关重要,以确定HER3-ADCs在固体瘤患者中的疗效和安全性.
持续的研究和数据收集对于优化HER3-ADC开发和临床应用至关重要.

关键词:

针对HER3的ADCs是针对HER3的.人类表皮生长因子受体3 (HER3)U3-1402) 已经得到了支持.抗体与药物联合体 (ADC)帕特里图马布德鲁克斯泰坎 (HER3-DXddcan) 是一种药物.固体瘤是一种固体瘤.有针对性的治疗.

更多相关视频

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.